NervGen Pharma (NervGen Pharma) Net Income From Continuing Operations : $-14.91 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. NervGen Pharma's net income from continuing operations for the three months ended in Mar. 2024 was $-1.73 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was $-14.91 Mil.

NervGen Pharma Net Income From Continuing Operations Historical Data

The historical data trend for NervGen Pharma's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma Net Income From Continuing Operations Chart

NervGen Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-7.42

-8.73

-9.94

-15.25

-16.68

NervGen Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-3.44	-3.58	-3.18	-6.42	-1.73

NervGen Pharma Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.91 Mil.

NervGen Pharma (NervGen Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (OTCPK:NGENF) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

9UA:Germany NGEN:Canada

Address

2955 Virtual Way, Suite 480, Vancouver, BC, CAN, V5M 4X6

Website

https://www.nervgen.com

NervGen Pharma Corp is a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases. The company is developing drugs for the treatment of spinal cord injury, multiple sclerosis, and Alzheimer's disease. It operates in a single segment, which is the research and development of pharmaceutical drugs.

NervGen Pharma (NervGen Pharma) Headlines

From GuruFocus

NervGen Pharma To Webcast At VirtualInvestorConferences.com July 11th

By PRNewswire PRNewswire • 07-09-2019